[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-immunodeficiency-diseases-pid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-immunodeficiency-diseases-pid":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,70,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100559511","a-database-survey-to-evaluate-the-safety-of-immune-globulin-subcutaneous-human-20-solution-in-participants-with-primary-immunodeficiency-100559511",false,"NCT06565078","A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency","Post-marketing Database Survey: A Cohort Study to Evaluate the Safety of Cuvitru in Patients With Primary Immunodeficiency Using the PIDJ2 (Primary Immunodeficiency Database in Japan) Registry","Inclusion Criteria:\n\n1. Patients with primary immunodeficiency (PID) enrolled in the PID patient registry.\n2. Participant for whom study drug is entered in the therapeutic drug field on the data set.\n3. Participant who is entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.\n4. Participant for whom the presence or absence of adverse events has been entered in the column of adverse events.\n\nExclusion Criteria:\n\n1. Participant for whom study drug has not been entered in the drug name in the medical history field during the period from January 24, 2024 to January 23, 2029.\n2. Participant who is not entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.\n3. Participant for whom the presence or absence of adverse events has not been entered in the column of adverse events.","ALL",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.",[23],"Primary Immunodeficiency Diseases (PID)",[25],"Primary immunodeficiency disease","RECRUITING","2026-02-18",{"date":29,"type":30},"2026-02-20","ACTUAL",{"date":32,"type":30},"2025-02-17",{"date":34,"type":19},"2030-07-31",{"name":36,"class":37},"Takeda","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":38},"100613077","ex-vivo-evaluation-of-jak-inhibitor-and-gene-therapeutical-approach-in-jak-stat-related-disorders-100613077","NCT07261891","Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders","Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders (JAKarta Study)","JAKarta","Inclusion Criteria:\n\n* Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway.\n* Controls (B): participants eligible for inclusion in this study must fall in one of the following categories:\n* Healthy controls (without immune-mediated disease)\n\nExclusion Criteria:\n\n* Children (\\\u003C 18 years at time of recruitment)\n* Persons unable or unwilling to give informed consent",true,"18 Years",{"count":50,"type":19},20,"INTERVENTIONAL",[53],"NA","The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy",[23],[57,58,59],"JAK inhibitors","STAT1 gain-of-function","gene therapy","2025-11-28",{"date":62,"type":30},"2025-12-03",{"date":64,"type":30},"2024-11-21",{"date":66,"type":19},"2030-12-01",{"name":68,"class":69},"prof. dr. Rik Schrijvers","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":51,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100594253","phase-3-efficacy-safety-and-pharmacokinetic-of-virchow-ivig-in-pid-patients-100594253","NCT07017036","Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients","An Open- Label, Multicentre, Phase III Clinical Comparative Study to Evaluate the Efficacy, Safety and Pharmacokinetic Properties of Human Normal Immunoglobulin in Patients With Primary Immunodeficiency Disease","VBPL-IVIGP3","Inclusion Criteria:\n\n1. Male or female, aged 2 to 65 years.\n2. Patients with confirmed diagnosis of primary immunodeficiency, predominantly antibody deficient, or common variable immunodeficiency (CVID) with a history of hypogammaglobulinemia (i.e., IgG\\\u003C500 mg\u002Fdl) or X-linked agammaglobulinemia (XLA).\n3. Treatment naive patients eligible to receive intravenous immunoglobulin or, patients already on intravenous immunoglobulin infusions every 3 or every 4 weeks for ≥6 months at a dose aimed to be between 200 and 800 mg\u002Fkg with at least two documented IgG trough levels in the previous two infusions before enrolment in the study.\n4. The screening laboratory tests must meet the following criteria:\n\n   1. WBC ≥3.5 x 109\u002FL\n   2. Neutrophils ≥1.5 x 109\u002FL\n   3. Platelets ≥100 x 109\u002FL\n   4. Serum transaminase ≤2 times the upper limit of normal\n   5. Alkaline phosphatase levels ≤2 times the upper limit of normal\n   6. Serum creatinine ≤150 µmol\u002FL (≤1.7mg\u002Fdl)\n5. Patients must be able to adhere to the study visit schedule and other protocol requirements.\n6. If subject is a female and is\n\n   a. -of child bearing potential, she should be practicing an acceptable method of birth control for the duration of tl1e study as suggested by the investigator, such as a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier method), intrauterine device (IUD), or abstinence OR surgically sterile, bilateral tubal ligation done at least 6 months before the study should be documented\n7. Patients\u002FLAR must be capable of giving informed consent, and written consent must have been obtained prior to any study procedures.\n\nExclusion Criteria:\n\n1. Pregnant women, nursing mothers or a planned pregnancy within 18 months of participation.\n2. Patients requires any blood transfusion during the study.\n3. Patients with T-cell related Severe combined immunodeficiency.\n4. Patients with secondary immunodeficiency diseases\n5. History or presence of any form of cancer prior to enrollment.\n6. History of any autoimmune disease\n7. Positive at screening for any markers of infectious blood borne viruses\n8. History of adverse or allergic reactions to other IgG or blood products\n9. Patients with selective IgA deficiency or antibodies IgA\n10. History of acute renal failure or severe renal impairment, or deep venous thrombosis which in the opinion of the Investigator, may place the patient at unacceptable risk for study participation and may prevent the patient from completing the study.\n11. History of congestive heart failure \\[New York Heart Association class III\u002FIV\\] or unstable angina\n12. Recent history of migraine, hyperprolinemia, and lymphoid malignancy.\n13. Requirement for use of glucocorticosteroids above 0.15 mg of prednisone equivalent\u002Fkg\u002Fday and other immunosupressive drugs as concomitant medication.\n14. History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the patient at unacceptable risk for study participation and may prevent the patient from completing the study.\n15. Participation in any clinical study within the previous 3 months\n16. Patient, who in the opinion of the Investigator, is not suitable for participation in the clinical study","2 Years","65 Years",{"count":81,"type":19},44,[83],"PHASE3","The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments",[23],[23],"NOT_YET_RECRUITING","2025-06-09",{"date":90,"type":30},"2025-06-12",{"date":92,"type":19},"2025-07-01",{"date":94,"type":19},"2026-12-01",{"name":96,"class":37},"Virchow Group",2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":47,"sex":16,"minAge":4,"maxAge":48,"enrollmentInfo":104,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100566012","inbon-errors-of-immunity-attending-assiut-university-childrenamp39s-hospital-a-single-center-study-100566012","NCT06649643","Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study","Inclusion Criteria:patients with the ten warning signs are four or more new ear\n\ninfections within 1 year,two or more serious sinus infections within 1 year,two or more months on antibiotics with little effect,two or more pneumonias within 1 year,failure of an infant to gain weight or grow normally,recurrent, deep skin or organ abscesses, persistent thrush in mouth or fungal infection on skin, need for intravenous antibiotics to clear infections,Two or more deep-seated infections including septicemia and family history of IEIs -\n\nExclusion Criteria:\n\n* patients without any criteria of ten warning signs",{"count":105,"type":19},60,"Aim of Study The aim of this study to describe the clinical profile of children diagnosed as IEIs who were admitted to in Assiut university children\\'s Hospital.",[23],"2024-10-18",{"date":110,"type":30},"2024-10-21",{"date":112,"type":19},"2025-01-05",{"date":114,"type":19},"2026-03-05",{"name":116,"class":69},"Assiut University"]